object
investig
etiolog
viral
respiratori
tract
infect
mainli
hospit
children
adult
consecut
period
implement
multiplex
nucleic
acid
amplif
test
total
respiratori
sampl
analyz
us
food
drug
administrationclear
esensor
respiratori
viral
panel
genmark
diagnost
carlsbad
ca
result
specimen
test
specimen
posit
least
one
viru
give
posit
rate
viral
codetect
total
viral
target
identifi
age
group
highest
posit
rate
year
age
group
overal
viral
codetect
rate
human
rhinoviru
hrv
preval
respiratori
viru
found
children
adult
peak
hrv
seen
septemb
repres
combin
hrv
enteroviru
epidem
respiratori
infect
conclus
abil
detect
wider
rang
respiratori
virus
gave
us
better
understand
etiolog
respiratori
infect
popul
particularli
hrv
enhanc
abil
detect
viral
coinfect
viral
infect
respiratori
tract
frequent
ill
seen
human
annual
million
peopl
afflict
worldwid
affect
age
group
particularli
young
elderli
chronic
medic
condit
specif
risk
group
respiratori
viral
infect
may
predispos
secondari
bacteri
infect
includ
pneumonia
otiti
media
sinus
lead
sever
outcom
hospit
death
emerg
new
respiratori
viral
pathogen
sever
acut
respiratori
syndrom
coronaviru
avian
influenza
pandem
influenza
discoveri
novel
virus
known
caus
respiratori
tract
infect
human
human
metapneumoviru
hmpv
increas
understand
lifethreaten
ill
associ
respiratori
infect
current
pharmacolog
intervent
respiratori
viral
infect
larg
limit
vaccin
therapeut
proven
valu
current
avail
respiratori
virus
influenza
develop
effect
vaccin
antivir
therapi
better
understand
diseas
etiolog
epidemiolog
necessari
driven
clinic
diagnost
laboratori
move
tradit
viral
cultur
timeconsum
limit
repertoir
new
molecular
diagnost
technolog
rel
rapid
permit
detect
wider
spectrum
viral
respiratori
pathogen
us
food
drug
administr
fda
clear
sever
nucleic
acid
amplif
respiratori
viral
panel
abl
detect
multipl
respiratori
virus
singl
test
septemb
genmark
diagnost
carlsbad
ca
receiv
clearanc
fda
esensor
respiratori
viral
panel
abl
detect
differ
viral
target
singl
test
nasopharyng
specimen
object
investig
studi
studi
etiolog
epidemiolog
respiratori
viru
infect
particular
determin
virusspecif
posit
rate
age
sex
distribut
viral
codetect
season
mainli
hospit
children
adult
midwest
univers
medic
center
implement
esensor
respiratori
viral
panel
consecut
period
sampl
januari
januari
prospect
specimen
test
nasopharyng
swab
nasal
wash
bronchoalveolar
lavag
esensor
respiratori
viral
panel
age
sex
patient
specimen
type
date
collect
test
result
record
respiratori
specimen
test
hospit
patient
univers
minnesota
medic
center
univers
minnesota
children
hospit
order
guidelin
state
assay
order
hospit
patient
respiratori
distress
evalu
sever
immunocompromis
critic
ill
patient
respiratori
symptom
put
place
avoid
misus
assay
assay
discourag
patient
seen
emerg
depart
ed
clinic
respiratori
viral
cultur
andor
rapid
antigen
test
respiratori
virus
recommend
altern
test
despit
specimen
submit
ed
outpati
clinic
per
physician
order
esensor
respiratori
viral
panel
fda
approv
nasopharyng
swab
thu
laboratori
perform
valid
bronchoalveolar
lavag
nasal
wash
specimen
assess
perform
characterist
assay
detect
intend
viral
target
specimen
type
valid
show
perform
characterist
assay
specimen
type
accept
agreement
publish
data
respiratori
specimen
type
nasopharyng
swab
bronchoalveolar
lavag
nasal
wash
disclaim
state
particular
specimen
type
valid
need
interpret
accordingli
attach
result
determin
period
time
necessari
differenti
new
infect
prolong
viru
presencepersist
previou
infect
review
literatur
perform
indic
case
viral
nucleic
acid
detect
beyond
day
initi
viral
infect
decid
studi
patient
repeat
specimen
sent
test
period
exclud
analysi
repeatedli
neg
repeatedli
posit
viru
esensor
respiratori
viral
panel
qualit
nucleic
acid
multiplex
vitro
diagnost
test
use
esensor
system
simultan
detect
identif
follow
viru
type
subtyp
influenza
subtyp
influenza
season
subtyp
influenza
season
subtyp
influenza
subtyp
influenza
b
respiratori
syncyti
viru
subtyp
rsv
respiratori
syncyti
viru
subtyp
b
rsv
b
parainfluenza
viru
parainfluenza
viru
parainfluenza
viru
hmpv
human
rhinoviru
hrv
adenoviru
speci
adv
adenoviru
speci
c
adv
c
nuclisen
easymag
autom
extractor
biomerieux
durham
nc
use
isol
viral
nucleic
acid
compliant
fdaapprov
extract
method
esensor
respiratori
viral
panel
categor
variabl
compar
use
v
test
twotail
p
valu
less
consid
signific
institut
review
board
applic
studi
submit
univers
minnesota
human
research
protect
program
review
approv
januari
januari
total
respiratori
sampl
consist
nasopharyng
swab
bronchoalveolar
lavag
nasal
wash
analyz
esensor
respiratori
viral
panel
specimen
test
pediatr
patient
age
day
year
adult
patient
age
year
posit
specimen
give
posit
rate
specimen
posit
one
viru
total
virus
detect
distribut
among
total
virus
follow
hrv
rsv
rsv
b
influenza
subtyp
hmpv
adv
adv
c
influenza
b
tabl
age
group
highest
posit
rate
total
posit
virus
per
age
grouptot
test
specimen
per
age
group
year
year
follow
year
tabl
number
pediatr
specimen
test
specimen
smaller
adult
specimen
highest
number
detect
virus
detect
virus
vs
detect
respect
hrv
common
viru
detect
age
group
except
year
older
highest
hrv
preval
seen
age
group
posit
hrv
rsv
common
viru
isol
hrv
age
group
posit
rsv
posit
rsv
age
group
influenza
main
caus
respiratori
infect
hrv
remain
age
group
equival
hrv
age
group
year
older
although
number
small
tabl
influenza
subtyp
detect
influenza
season
subtyp
detect
studi
period
adv
c
preval
adv
detect
vs
tabl
highest
number
posit
adv
c
seen
age
group
tabl
preval
piv
subtyp
posit
specimen
vs
posit
posit
tabl
specimen
test
femal
patient
male
patient
total
posit
rate
femal
patient
total
femal
posit
viral
target
total
femal
specimen
test
male
patient
total
male
posit
viral
target
total
male
specimen
test
p
number
posit
viral
target
male
higher
femal
age
group
except
older
age
group
femal
higher
number
posit
viral
target
male
age
group
greatest
differ
male
femal
posit
rate
age
group
posit
rate
respect
p
seventytwo
specimen
one
viru
detect
thu
give
codetect
rate
total
posit
specimen
total
specimen
test
tabl
infant
year
young
children
year
age
group
highest
codetect
rate
respect
tabl
frequent
codetect
combin
hrv
adv
c
hrv
rsv
influenza
preval
colder
month
year
show
peak
novemb
present
year
peak
spring
month
adenoviru
c
seen
year
around
peak
late
fall
winter
hmpv
seen
age
group
year
around
highest
number
posit
decemb
march
april
may
introduct
nucleic
acid
test
clinic
virolog
laboratori
enhanc
abil
detect
virus
abl
recov
tradit
viral
cultur
method
thu
permit
us
identifi
hidden
burden
viral
respiratori
infect
patient
popul
hrv
preval
respiratori
viru
popul
specimen
posit
hrv
repres
specimen
test
hospit
patient
includ
children
age
year
younger
hrv
previous
consid
respiratori
viru
minim
pathogen
emerg
caus
sever
respiratori
ill
healthi
individu
underli
asthma
vulner
popul
young
elderli
immunocompromis
hrv
respons
common
cold
like
symptomat
children
adult
shown
better
identif
germ
longitudin
viral
epidemiolog
studi
hrv
famili
includ
three
speci
hrva
hrvb
hrvc
within
speci
multipl
serotyp
type
strain
recent
describ
speci
hrvc
associ
seriou
lower
respiratori
diseas
infant
young
children
elderli
person
immunocompromis
patient
studi
larg
peak
posit
hrv
detect
seen
septemb
rais
question
particularli
coincid
enteroviru
outbreak
upon
investig
demonstr
genmark
diagnost
hrv
primer
probe
use
esensor
respiratori
viral
panel
crossreact
enteroviru
thu
high
posit
hrv
peak
seen
septemb
repres
combin
hrv
epidem
enteroviru
also
demonstr
pediatr
popul
higher
burden
viral
respiratori
infect
compar
adult
test
specimen
pediatr
patient
highest
number
detect
virus
detect
virus
compar
detect
virus
test
adult
specimen
p
rsv
common
viru
detect
young
children
age
group
hrv
rsv
caus
sever
infect
infant
young
children
import
etiolog
agent
acut
lower
respiratori
tract
infect
infant
young
children
unit
state
worldwid
studi
hmpv
preval
infant
young
children
older
popul
age
group
consist
previou
studi
hmpv
high
preval
bronchiol
pneumonia
hospit
infant
young
children
advanc
age
underli
cardiopulmonari
diseas
two
risk
factor
sever
hmpv
infect
older
popul
influenza
influenza
influenza
b
r
v
r
v
b
hmpv
parainfluenza
viru
subtyp
subtyp
commonli
associ
bronchiol
bronchiti
pneumonia
thu
often
requir
hospit
admiss
clinic
manag
studi
respiratori
specimen
hospit
patient
preval
piv
subtyp
caus
coldlik
symptom
infect
peopl
may
caus
mild
sever
respiratori
tract
ill
infect
patient
could
assess
preval
studi
target
includ
esensor
respiratori
viral
panel
adv
import
pathogen
infant
also
detect
frequent
respons
approxim
report
childhood
viral
respiratori
infect
global
caus
broad
spectrum
clinic
diseas
includ
respiratori
tract
infect
immunocompromis
host
adv
caus
sever
local
diseas
dissemin
diseas
multiorgan
failur
viral
codetect
defin
detect
one
viral
pathogen
specimen
phenomenon
underestim
use
viral
cultur
sinc
introduct
new
technolog
move
diagnosi
abil
forward
capabl
detect
one
viru
per
specimen
greatli
increas
understand
true
incid
viral
coinfect
viral
codetect
seen
posit
specimen
studi
hrv
viru
commonli
associ
virus
clinic
signific
viral
codetect
thu
possibl
coinfect
unclear
review
literatur
conflict
studi
link
viral
coinfect
sever
clinic
outcom
show
overal
differ
singl
respiratori
viru
infect
viral
coinfect
also
shown
studi
tabl
viral
codetect
appear
commonli
seen
pediatr
patient
adult
reason
differ
known
even
though
impact
viral
coinfect
sever
diseas
unclear
need
rapid
accur
detect
wide
spectrum
viral
respiratori
pathogen
desir
understand
correl
clinic
ill
epidemiolog
hospit
infect
control
reason
field
clinic
virolog
chang
dramat
sinc
introduct
new
diagnost
techniqu
clinic
laboratori
newer
assay
still
develop
expand
number
detect
target
includ
viral
bacteri
respiratori
pathogen
coronaviru
bordetella
speci
decreas
turnaround
time
increas
understand
circul
respiratori
pathogen
differ
season
year
differ
health
care
set
hospit
base
vs
commun
base
potenti
help
develop
new
vaccin
continu
advanc
diagnost
technolog
enabl
diagnost
microbiolog
laboratori
expand
capabl
detect
respiratori
virus
thu
help
understand
epidemiolog
respiratori
virus
evid
mani
unansw
question
still
need
address
exampl
scientif
reason
behind
season
differ
respiratori
virus
antivir
treatment
use
treat
viral
respiratori
tract
infect
despit
progress
made
centuri
still
common
oral
antivir
therapi
avail
treatment
respiratori
virus
except
influenza
studi
need
conduct
answer
question
studi
limit
fact
clinic
data
associ
test
result
thu
could
assess
symptom
associ
viral
infect
coinfect
diseas
progress
treatment
plan
respons
treatment
note
nineteen
specimen
compos
tracheal
aspir
sputum
throat
swab
exclud
analysi
perform
characterist
specimen
type
valid
esensor
respiratori
viral
panel
thu
accuraci
result
could
verifi
